By Jaime Llinares Taboada

 

AstraZeneca PLC said Thursday that Phase 3 trials on its AZD7442 antibody combination confirmed that the treatment reduces risk of developing symptomatic Covid-19.

The pharmaceutical company said the analysis of its continuing trial evaluating a median six months of participant follow-up revealed that one dose of AZD7442 showed 83% reduced symptomatic Covid-19 risk and no severe disease or deaths.

A separate trial in patients with mild-to-moderate Covid-19 showed that a larger dose of AZD7442 reduced risk of severe Covid-19 or death by 88% compared to placebo, in patients who had been symptomatic for three days or fewer at the time of the treatment.

"These compelling results give me confidence that this long-acting antibody combination can provide my vulnerable patients with the long-lasting protection they urgently need to finally return to their everyday lives," Hugh Montgomery, a professor at University College London and AZD7442 principal investigator, said.

 

Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT

 

(END) Dow Jones Newswires

November 18, 2021 03:00 ET (08:00 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Dez 2021 até Jan 2022 Click aqui para mais gráficos Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Jan 2021 até Jan 2022 Click aqui para mais gráficos Astrazeneca.